A top-selling product is linked with cancer. Campaigners globally want to ban its main ingredient. The company’s response? A promise to spend €5 billion ($8.2 billion) over 10 years on alternatives.
Bayer’s move concerning glyphosate, a controversial weedkiller, created good publicity. It will not free the German chemicals and drugs group from creepers entangling it since last year’s $US63 billion ($91.5 billion) purchase of US rival Monsanto.
